Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC step-therapy Prior Auth …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Formulary step-therapy and prior authorization criteria for selected pharmacy products

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists prior authorization/step therapy requirements and continuation rules for several outpatient prescription drugs on the Blue Cross Blue Shield - South Carolina formulary. It affects prescribers and pharmacy benefit administrators managing new starts and continuations for the listed products.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step-therapy and prior authorization criteria for selected pharmacy products
    Policy CodePolicy N/A
    Change TypeMinor — no material clinical or coverage changes
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionDocument trials of required alternative agents for new starts and approve continuation when prior use is documented.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~12distinct product entries
    Version 10formulary version
    03/01/2026effective date
    02/02/2026last updated
    1explicit drug shown
    15document chunks

    Coverage Criteria — Product-specific Initial Therapy

    inv-01: Diclofenac Sodium GEL 3% — Listing

    Diclofenac Sodium GEL 3% is listed as an affected product.

    Product listing: Diclofenac Sodium GEL 3% listed as affected product

    Formulary entry; Criteria note: trial of either topical fluorouracil or topical imiquimod (see Formulary ID details)

    inv-02: Antidepressant products — Initial Therapy

    Covered when ALL of the following are met for new starts:

    Antidepressant trial requirement: Trial of two generics from: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride2 agents

    Approve for continuation of prior therapy

    inv-03: Fanapt and related products — Initial Therapy

    Covered when ALL of the following are met for new starts:

    Atypical antipsychotic trial requirement: Trial of two generics from: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone2 agents

    Approve for continuation of prior therapy

    inv-04: Invega Hafyera — Initial Therapy

    Covered when ALL of the following are met for new starts:

    Invega Hafyera trial requirement: Trial of one of: Invega Sustenna or Invega Trinza1 agent

    Step applies to new starts only; approve for continuation of prior therapy

    inv-05: Relistor — Initial Therapy

    Covered when ALL of the following are met:

    Relistor trial requirement: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose1 agent

    Approve for continuation of prior therapy

    inv-06: Rytary — Initial Therapy

    Covered when ALL of the following are met for new starts:

    Rytary trial requirement: Trial of one generic carbidopa/levodopa-containing formulation1 agent

    Step applies to new starts only; approve for continuation of prior therapy

    inv-07: Zonisade — Initial Therapy

    Covered when ALL of the following are met for new starts:

    Zonisade trial requirement: Trial of a generic zonisamide capsule1 agent

    Step applies to new starts only; approve for continuation of prior therapy

    This section is an index listing and does not contain specific coverage criteria text. The document segment repeats drug names and topical headings (for example, Diclofenac Sodium and class headings such as Antidepressants and Atypical Antipsychotics) for navigation rather than presenting eligibility requirements.

    This section is an index listing and does not define coverage criteria or exclusions. It lists product names used for navigation (for example, Emsam, Exxua, and Exxua Titration Pack) but does not include the policy criteria for those entries in this fragment.

    Initial Therapy — Step and Trial Requirements

    inv-84: Antidepressant initial therapy

    Initial therapy requirements for antidepressant-class products.

    Antidepressant initial therapy: Trial of two generics from specified list for new starts (bupropion, mirtazapine, citalopram [tablet or solution], desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride)2 agents

    Continuation approvable

    inv-85: Atypical antipsychotic initial therapy

    Initial therapy requirements for atypical antipsychotic-class products.

    Atypical antipsychotic initial therapy: Trial of two generics from specified list for new starts (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)2 agents

    Continuation of Prior Therapy

    inv-90: Continuation of prior therapy — approvable when documented

    Continuation of prior therapy is approvable for listed products when documented.

    Continuation approval: Continuation of prior therapy is approvable for products with step requirements when prior use is documented

    Appears repeatedly across entries

    Step Therapy — Required Trials and Alternatives

    Drug/ClassRequired prior trials (new starts)Notes
    Antidepressant-class productsTrial of two generics from: bupropion; mirtazapine; citalopram (tablet or solution); desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine hydrochlorideApplies to new starts; approve continuation of prior therapy
    Atypical antipsychotic-class products (e.g., Fanapt and titration packs)Trial of two generics from: asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidoneApplies to new starts; approve continuation of prior therapy
    Invega HafyeraTrial of one of: Invega Sustenna or Invega TrinzaStep applies to new starts only; approve continuation of prior therapy
    ZonisadeTrial of a generic zonisamide capsuleStep applies to new starts only; approve continuation of prior therapy

    Provider Actions — Documentation, Denial Risks, and Operational Notes

    Note

    Diclofenac Sodium GEL 3% listed (no PA text)

    Diclofenac Sodium GEL 3% is listed as a product affected in this segment; no specific prior authorization or step requirements are provided in this fragment.

    Prior Authorization

    Antidepressant new-starts: trial of two generics required

    For new starts, require documentation of a trial of two generic antidepressant agents from the listed options; continuation of prior antidepressant therapy should be approved when prior use is documented.

    • Trial of two generics from: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride.
    • Approve continuation when prior therapy is documented.

    Definitions and Index Terms

    Index Of Drugs — key/value
    Diclofenac Sodium GEL 3%Index entry — see topical NSAID listing and page reference
    AntidepressantsIndex entry — refers to antidepressant products and score/page listing
    Atypical AntipsychoticsIndex entry — refers to atypical antipsychotic products and score/page listing
    Index fragment (key/value)
    EmsamIndex entry — listed on page 2
    ExxuaIndex entry — listed on page 2
    Exxua Titration Pack

    Background and Scope Notes

    The provided fragment does not contain clinical background material. It is an index of drugs and topical policy sections that repeats product names and page references (for example, Diclofenac Sodium, class headings such as Antidepressants and Atypical Antipsychotics), and therefore no clinical background information is available in this segment.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyFormulary step-therapy and prior authorization criteria for selected pharmacy products
    Policy CodePolicy N/A
    Change TypeMinor — no material clinical or coverage changes
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateN/A
    Key ActionDocument trials of required alternative agents for new starts and approve continuation when prior use is documented.
    SourceLink
    On This Page
    Coverage Criteria — Product-specific Initial TherapyInitial Therapy — Step and Trial RequirementsContinuation of Prior TherapyStep Therapy — Required Trials and AlternativesProvider Actions — Documentation, Denial Risks, and Operational NotesDefinitions and Index TermsBackground and Scope Notes

    Continuation approvable

    inv-86: Invega Hafyera initial therapy

    Initial therapy requirement for Invega Hafyera.

    Invega Hafyera initial therapy: Trial of Invega Sustenna or Invega Trinza for new starts1 agent

    Continuation approvable

    inv-87: Relistor initial therapy

    Initial therapy requirement for Relistor.

    Relistor initial therapy: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose1 agent

    Continuation approvable

    inv-88: Rytary initial therapy

    Initial therapy requirement for Rytary.

    Rytary initial therapy: Trial of one generic carbidopa/levodopa formulation1 agent

    Continuation approvable

    inv-89: Zonisade initial therapy

    Initial therapy requirement for Zonisade.

    Zonisade initial therapy: Trial of generic zonisamide capsule1 agent

    Step applies to new starts only; continuation approvable

    Prior Authorization

    Fanapt new-starts: trial of two generic atypical antipsychotics

    For Fanapt and its titration packs, require documentation of trials of two generic atypical antipsychotics from the listed options for new starts; continuation of prior Fanapt therapy should be approved when prior use is documented.

    • Trial of two generics from: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone.
    • Approve continuation when prior therapy is documented.
    Prior Authorization

    Invega Hafyera new-start: trial of Sustenna or Trinza

    For new starts of Invega Hafyera, require documentation of a trial of Invega Sustenna or Invega Trinza; the step requirement applies to new starts only and continuation of prior therapy should be approved when documented.

    • Trial of one of: Invega Sustenna or Invega Trinza.
    • Step applies to new starts only; approve continuation with documentation of prior use.
    Note

    Index entry — no prior authorization specified

    This index fragment does not specify any prior authorization requirements.

    Note

    Index — no prior authorization rules

    This index section lists drug names and navigation entries only and does not specify prior authorization rules.

    Note

    Index only — no prior authorization specified

    These index-only chunks do not contain prior authorization requirements; they are navigational listings referencing other policy pages.

    Note

    Prior authorization — none in fragment

    No prior authorization requirements are stated in this fragment; it is an index listing without authorization details.

    Note

    Prior authorization not listed here (index excerpt)

    No prior authorization requirements are specified in this index excerpt; it provides drug names and page references only.

    Note

    Index — no PA specified

    This index fragment is navigational only and does not specify prior authorization requirements.

    Note

    Prior authorization — not specified in index

    Index entries here do not specify prior authorization requirements; only drug names and titration pack references are listed.

    Note

    Index-only: no prior authorization rules

    No prior authorization requirements are listed in this index-only portion.

    Note

    Prior authorization — none listed

    This index portion does not list prior authorization requirements; it is for navigation to other sections.

    Note

    Index — no prior auth details

    No prior authorization requirements are provided in this index fragment.

    Note

    Prior authorization (index) — no details

    This index listing does not state any prior authorization requirements.

    Note

    Prior authorization not specified in index

    No prior authorization requirements are specified in this index excerpt; it lists drug and titration pack names only.

    Note

    Prior authorization not specified

    This fragment is an index/listing and does not include prior authorization requirements.

    Note

    Prior authorization not listed here

    No prior authorization requirements are specified in this index fragment.

    Step Therapy

    Step therapy applies to new starts only; continuation approvable

    Step therapy requirements described in the policy apply to new starts only; continuation of prior therapy should be approved when prior use is documented.

    • Step requirements apply to new starts only.
    • Approve continuation when prior therapy is documented.
    Note

    Provider-action index fragment — no step rules present

    This index fragment does not contain step therapy rules; it is for navigation only.

    Note

    Provider-action index fragment — no step rules present

    No step therapy rules are present in this index portion; consult the specific drug pages for requirements.

    Note

    Provider-action index fragment — no step rules present

    This index fragment contains no step therapy requirements and is navigational only.

    Note

    Provider-action index fragment — no step rules present

    No step therapy rules are present in this index fragment; it lists drugs and page references only.

    Note

    Provider-action index fragment — no step rules present

    This part of the index does not include step therapy requirements; it is for navigation.

    Note

    Provider-action index fragment — no step rules present

    No step therapy rules are provided in this index fragment.

    Note

    Provider-action index fragment — no step rules present

    This index fragment does not include any step therapy requirements; it is navigational only.

    Note

    Provider-action index fragment — no step rules present

    No step therapy rules are present in this index portion.

    Note

    Provider-action index fragment — no step rules present

    This index fragment contains no step therapy requirements; consult specific policy pages for details.

    Note

    Provider-action index fragment — no step rules present

    No step therapy rules are provided in this index fragment.

    Note

    Provider-action index fragment — no step rules present

    This index fragment does not include step therapy requirements; it serves navigation.

    Note

    Provider-action index fragment — no step rules present

    No step therapy rules are present in this index portion; consult the drug-specific sections.

    Note

    Provider-action index fragment — no step rules present

    This index fragment contains no step therapy rules; use the specific formulary entries for requirements.

    Note

    Provider-action index fragment — no step rules present

    No step therapy rules are provided in this index fragment.

    Note

    Index entries for Fanapt/titration packs — navigation only

    This index fragment does not specify step therapy requirements; it lists Fanapt titration packs for navigation only.

    Documentation Required

    Index-only — no documentation requirements

    No documentation requirements are specified in this index fragment.

    Documentation Required

    Index-only — no documentation requirements

    No documentation requirements are specified in this index fragment.

    Documentation Required

    Index-only — no documentation requirements

    No documentation or authorization requirements are provided in this index section; it lists drug names and page numbers only.

    Documentation Required

    Index-only — no documentation requirements

    This chunk contains only index entries and does not include documentation requirements.

    Documentation Required

    Index-only — no documentation requirements

    No documentation requirements are specified in these index pages.

    Documentation Required

    Index-only — no documentation requirements

    No documentation requirements are specified in this index fragment.

    Documentation Required

    Index-only — no documentation requirements

    No documentation requirements are specified in this index fragment.

    Documentation Required

    Index-only — no documentation requirements

    No documentation requirements are specified in the index pages included in these chunks.

    Documentation Required

    Fanapt/titration pack index — no documentation requirements

    Index entries for Fanapt and its titration packs are provided for navigation; no documentation requirements are specified in these chunks.

    Documentation Required

    Document antidepressant trials (two generics)

    Document trials of two generic antidepressant agents when required for new starts; include agent names and dates to support continuation or new-start approvals.

    • Record the two generic agents tried and treatment dates.
    • Include documentation of prior use to support continuation approvals.
    Documentation Required

    Document atypical antipsychotic trials (two generics)

    Document trials of two generic atypical antipsychotics for Fanapt and related products when required; include agent names and dates to support approval or continuation.

    • Record the two generic atypical antipsychotics tried and treatment dates.
    • Include documentation of prior use to support continuation approvals.
    Note
    Note
    Note
    Note
    Denial Risk

    Denial risk: Rytary — document generic carbidopa/levodopa trial

    For Rytary new starts, failure to document a trial of one generic carbidopa/levodopa formulation may trigger denial of coverage.

    • Document the specific generic carbidopa/levodopa formulation tried, with dates.
    Denial Risk

    Denial risk: Relistor — document trial of listed laxatives

    For Relistor, failure to document a trial of one of the listed laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose) may trigger denial.

    • Document which laxative was tried and the treatment dates.
    Note

    Index fragment — no authorization/denial criteria present

    This index fragment does not include authorization or denial criteria; it is navigational only.

    Note

    Index fragment — no authorization/denial criteria present

    This index fragment lists drugs and topics for navigation and does not state authorization or denial triggers.

    Note

    Index fragment — no authorization/denial criteria present

    No authorization or denial criteria are present in these index pages; consult specific drug sections for requirements.

    Note

    Index fragment — no authorization/denial criteria present

    This index fragment contains no authorization or denial criteria and serves navigation only.

    Note

    Index fragment — no authorization/denial criteria present

    No authorization or denial criteria are present in this index fragment.

    Note

    Index fragment — no authorization/denial criteria present

    This index fragment is navigational and does not include authorization or denial criteria.

    Note

    Index fragment — no authorization/denial criteria present

    No authorization or denial criteria are provided in this index section; it lists drug names and page references only.

    Note

    Index fragment — no authorization/denial criteria present

    This index fragment contains no authorization or denial criteria; use the detailed product pages for requirements.

    Note

    Index fragment — no authorization/denial criteria present

    No authorization or denial criteria are present in this index fragment.

    Note

    Index fragment — no authorization/denial criteria present

    This index fragment is navigational only and does not include authorization or denial criteria.

    Note

    Index fragment — no authorization/denial criteria present

    No authorization or denial criteria are present in this index fragment.

    Note

    Index fragment — no authorization/denial criteria present

    This index fragment does not include authorization or denial criteria; it lists drug names for navigation.

    Note

    Index fragment — no authorization/denial criteria present

    No authorization or denial criteria are present in this index fragment.

    Note

    Index entries for Fanapt and titration packs — navigation only

    This index fragment lists Fanapt titration packs for navigation and does not specify documentation or authorization requirements.

    Index entry — listed on page 2 (titration pack)
    Index of Drugs — navigation
    Exxua Titration PackIndex navigation entry — appears repeatedly with page 2 reference
    EmsamIndex navigation entry — appears with page 2 reference
    ExxuaIndex navigation entry — appears with page 2 reference
    Titration Pack — definition
    Definition: Titration PackA packaged set of initial dosing supplies used to titrate a medication during initiation (e.g., Exxua Titration Pack)
    Example: Exxua Titration PackListed in index as a titration pack with page reference 2
    Related: Fetzima Titration PackAlso listed as a titration pack in the index
    Index Of Drugs — key/value listing
    Exxua Titration PackIndex entry — repeated listing for navigation on page 2
    EmsamIndex entry — repeated listing on page 2
    Fetzima Titration PackIndex entry — listed in index alongside other titration packs
    Index fragment (key/value)
    EmsamIndex entry — appears repeatedly with page 2 reference
    ExxuaIndex entry — appears repeatedly with page 2 reference
    Exxua Titration PackIndex entry — repeated titration pack listing
    Index of Drugs — key/value
    Exxua Titration PackIndex entry — repeated navigation listing (page 2)
    ExxuaIndex entry — repeated navigation listing (page 2)
    Exxua Titration Pack (repeats)Multiple repeated index occurrences used for navigation
    Fanapt Titration Pack A — index entry
    FanaptIndex entry — listed with page reference 3
    Fanapt Titration Pack AIndex entry — listed with page reference 3 (titration pack variant)
    Fanapt Titration Pack BIndex entry — listed as an additional titration pack variant